bioMérieux S.A. (BMXXY)
bioMérieux S.A. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Marcy l'Étoile, ARA, FR. The stock last traded at $8.82, up 0.00% on the session, giving a market capitalisation of $10.40B. On trailing twelve-month figures it carries a trailing P/E of 18.59, a net margin of 11.6%. Its beta of 0.57 implies it has historically moved less than the broad market.
bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. Its operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides sophisticated diagnostic platforms that analyze biological specimens to pinpoint infectious diseases, cardiovascular conditions, and various cancers. Additionally, it offers microbiological testing for quality control in manufacturing, serving the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele encompasses clinical and hospital laboratories, medical practitioners, blood banks, and industrial control facilities. Founded in 1963, the company, previously known as B-D Mérieux, maintains its headquarters in Marcy l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA.
bioMérieux S.A. is most often compared with the following Healthcare names: